AMEND news in Month: November 2024
-
Survey on Pregnancy in MEN Patients
Dr Ruth Casey from the University of Cambridge Hospitals NHS Trust would be grateful for any ladies who have been pregnant since their MEN1, MEN2A or MEN2B diagnosis, or who are currently planning on becoming pregnant, to complete her short survey to provide an up-to-date picture on counselling given before/during pregnancy.
Click here to take the survey
-
AMEND Co-Authors Article on MEN2
We were honoured to be invited by surgeon, Mr Tom Kurzawinski, to co-write an article for the journal, Endocrine-Related Cancer, about patient experiences of living with a RET gene mutation (causing MEN2 and MEN3).
Click here to learn more
-
Genomics England New-born Screening
Back in August, Genomics England removed the RET gene (that causes MEN2/3) from their new-born screening research study. AMEND submitted a response expressing disappointment at this decision. We are grateful to Clinical Geneticists, Drs Fiona Lalloo and Louise Izatt, for working with the research team on this, which has resulted in RET mutation codon 918 (MEN2B) being reinstated into the study at the next phase.
Click here to learn more about the new-born screening programme
-
Survey for MEN Patients
The European MEN Alliance (EMENA), of which AMEND is an active member, has developed a survey for anyone affected by MEN syndromes, to find out what affected patients, partners and parents, consider to be the unmet needs in the patient pathways. Thank you for taking your time to complete this important survey.
Click here to take the survey
-
Christmas Shopping in Aid of AMEND
Visit our website shop for Christmas Cards, and our sustainable cotton clothing, with all profits going to supporting AMEND's work for the rare endocrine syndrome and tumour communities.
Click here to visit our shop